GD
Gregory J Divis
Chief Executive OfficerDirector

Gregory J Divis insider trades: Avadel Pharmaceuticals (AVDL) stock purchases

Chief Executive Officer, Avadel Pharmaceuticals Last trade Dec 9, 2024 31 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2017
3
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Gregory reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Dec 9, 2024AVDL↑ Buy$100K
Aug 10, 2023AVDL↑ Buy$132K
May 27, 2022AVDL↑ Buy$102K
Aug 12, 2020AVDL↑ Buy$101K
Nov 15, 2019AVDL↑ Buy$97K
Jun 26, 2018AVDL↑ Buy$96K
Sep 12, 2017AVDL↑ Buy$99K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AVDL insiders

Open-market trades in the last 12 months

About Gregory J Divis's insider trades

Gregory J Divis is Chief Executive Officer at Avadel Pharmaceuticals (AVDL). Since Sep 12, 2017, Gregory has reported 7 open-market purchases worth $728K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (20 filings), option exercises (2 filings), shares returned to the company (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVDL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.